Resource Summary Report

Generated by dkNET on Sep 1, 2026

Karpas-299

RRID:CVCL_1324
Type: Cell Line

Proper Citation

RRID:CVCL_1324

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1324

Proper Citation: RRID:CVCL_1324

Description: Cell line Karpas-299 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Anaplastic large cell lymphoma, ALK-positive

Defining Citation: PMID:3260522, PMID:8558920, PMID:9738977, PMID:9787181, PMID:11021758, PMID:11494142, PMID:15356658, PMID:17170727, PMID:20164919, PMID:20922763, PMID:22460905, PMID:25355872, PMID:26589293, PMID:26657151, PMID:27397505, PMID:28196595, PMID:28356514, PMID:29899875, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Karpas-299

Synonyms: KARPAS-299, Karpas 299, KARPAS 299, Karpas299, KARPAS299, K299

Cross References: BTO:BTO_0002829, CLO:CLO_0007065, EFO:EFO_0005390, CLDB:cl2995, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:624, BioSample:SAMN03473348, BioSample:SAMN10988031, cancercelllines:CVCL_1324,

Cell_Model_Passport:SIDM01010, ChEMBL-Cells:CHEMBL3308327, ChEMBL-Targets:CHEMBL2366156, Cosmic:850199, Cosmic:907273, Cosmic:1086364, Cosmic:1086752, Cosmic:1509203, Cosmic:1995466, Cosmic:2674498, Cosmic-CLP:907273, DepMap:ACH-000053, DSMZ:ACC-31, DSMZCellDive:ACC-31, ECACC:06072604, EGA:EGAS00001000978, GDSC:907273, GEO:GSM887195, GEO:GSM888268, GEO:GSM1217153, GEO:GSM1669975, IARC_TP53:21427, LiGeA:CCLE_563, LINCS_LDP:LCL-1117, Lonza:18, PharmacoDB:KARPAS299_729_2019, PRIDE:PXD030304, Progenetix:CVCL_1324, PubChem_Cell_line:CVCL_1324, Wikidata:Q54899495, Ximbio:152418

ID: CVCL_1324

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260829T234401+0000

Ratings and Alerts

No rating or validation information has been found for Karpas-299.

Warning: Discontinued: DSMZ; ACC-31
Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. Nature communications, 17(1), 759.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V?9V?2 T cell cytotoxicity against autologous and cancer cells. Cell reports, 44(10), 116387.

Abdelhamed S, et al. (2025) PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors. Molecular cancer therapeutics, 24(7), 963.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Coats JT, et al. (2024) Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition. Cancer research communications, 4(11), 3013.

Liu P, et al. (2024) Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma. American journal of cancer research, 14(6), 2921.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer research communications, 4(6), 1441.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics, 23(1), 68.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. Cell metabolism, 35(4), 633.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. Cell reports, 40(3), 111077.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115.

Muliaditan T, et al. (2021) Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell reports. Medicine, 2(12), 100457.